Impotence following delayed repair of prostatomembranous urethral disruption.

C. Dhabuwala,S. Hamid,D. Katsikas,J. Pierce

DOI: https://doi.org/10.1016/S0022-5347(17)39552-6

1990-09-01

Abstract:

What problem does this paper attempt to address?

Gastric Cancer with Breast Metastasis: Clinical Features and Prognostic Factors

Yue Ma,Wenwen Liu,Junjian Li,Yingchun Xu,Hongxia Wang

DOI: https://doi.org/10.3892/ol.2018.9383

2018-01-01

Oncology Letters

Abstract:Metastatic spread of gastric carcinoma to the breast is rare. In previous decades, reports on this subject were minimal and primarily limited to case reports. At present, little is known on the clinicopathological features and prognosis of this condition, and breast metastasis remains a challenging clinical problem. A total of 54 cases of breast metastasis from gastric cancer were collected from databases between January 1960 and December 2016. The present study included 3 cases of gastric cancer with breast metastasis from Renji hospital and 51 additional cases from previous studies. The clinicopathological features of patients, including epidemiology, symptoms, macroscopic presentation, pathological diagnosis, imaging, treatment and overall survival time, were analyzed. The median survival time was 8.6 months. All but one of the patients were female, and the median age at diagnosis of breast metastasis was 43 years old (age range, 22-72 years). A majority of patients presented with Borrmann class III disease, signet ring cell carcinoma, T4 tumor types, lymph node involvement, initial stage IV gastric cancer, primary lesions in the gastric antrum, left breast metastasis and palpable breast nodules. The median interval between the primary gastric carcinoma diagnosis and presentation of breast metastasis was 1.25 months (range, 0-72 months). The expression of the estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2 and gross cystic disease fluid protein-15 was negative in the patients with breast metastases. In univariate analysis, age, gastric tumor size, gastric lymph node involvement and breast metastasis histology were significantly associated with overall survival (OS) time (P=0.001, 0.039, 0.034 and <0.001, respectively). Therapeutically, gastric surgery and chemotherapy were not associated with OS (P=0.959 and 0.290, respectively). In further multivariate analysis, the time between occurrence (P=0.017), age (P=0.009), histology (P=0.045) and breast metastasis localization (P=0.043) were independent indicators of OS time. Although breast metastasis from gastric cancer is rare, physicians should be vigilant when patients with a history of gastric cancer present with newly developed mammary symptoms and signs.
Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care

Rudolf Weide,Stefan Feiten,Christina Waßmann,Bernhard Rendenbach,Ute Braun,Oswald Burkhard,Peter Ehscheidt,Marcus Schmidt

DOI: https://doi.org/10.3390/cancers16071255

2024-03-24

Cancers

Abstract:Overall survival (OS) of patients with metastatic breast cancer (MBC) has improved within controlled clinical trials. Whether these advances translate into improved OS in routine care is controversial. We therefore analyzed retrospectively unselected female patients from five oncology group practices and one university outpatient clinic, whose initial diagnosis of MBC was between 1995 and 2022. A total of 1610 patients with a median age of 63 years (23–100) were evaluated. In all, 82.9% had hormone-receptor-positive disease, and 23.8% were HER2-positive. Evaluation in time cohorts by initial MBC diagnosis date showed a continuous prolongation of median OS from 31.6 months (0.5–237.3+) (1995–2000) to 48.4 months (0.4–61.1+) (2018–2022) (p = 0.003). Univariable analyses showed a significant dependence on the time cohort of diagnosis, metastatic status at initial diagnosis, age at metastasis, hormone and HER2 status, general condition, metastasis localization, and the number of affected organs. A multivariable analysis revealed a significant dependence of survival probability on receptor status, general condition, and number of metastatic sites, as well as the time between initial breast cancer diagnosis and the diagnosis date of MBC in months. In sum, OS of patients with MBC has improved continuously and significantly in routine care over the last 27 years.

oncology
Curative Approaches for Metaplastic Breast Cancer: A Retrospective Cohort Outcome Review

Ling Fung Nelson Yit,Zhan Hong Sheriff Quek,Tira J Tan,Boon Fei Tan,Puay Hoon Tan,Kiat Tee Benita Tan,Yirong Sim,Fuh Yong Wong

DOI: https://doi.org/10.1016/j.ijrobp.2024.06.016

2024-12-01

Abstract:Purpose: Metaplastic breast cancer (MBC) is a rare and heterogeneous breast cancer subtype, and there are critical gaps in our understanding of its long-term outcomes. This retrospective cohort study aimed to address these gaps by scrutinizing the pathologic and clinical aspects of MBC to enhance clinical decision-making and refine patient care strategies. Methods and materials: This registry-based retrospective cohort study included women aged ≥21 years diagnosed with MBC or matrix-producing carcinoma. The data were obtained from January 2001 to August 2020 from the Joint Breast Cancer Registry of Singapore Health Services, which included 23,935 patients. Demographic and clinicopathologic characteristics, neoadjuvant chemotherapy responses, and survival outcomes were analyzed. Statistical assessments involved univariate and multivariate Cox proportional hazards models and Kaplan-Meier survival analyses. Results: This study enrolled 170 patients; 87.1% had non-metastatic disease, and 12.9% had metastatic disease. The age of patients at diagnosis ranged from 46 to 65 years (median, 56 years). The cohort's predominant characteristics were triple negative breast cancer (64%), advanced clinical stage (77.6%), node negativity (67.6%), and grade 3 disease (74.1%). In patients receiving neoadjuvant chemotherapy with curative intent treatment (17.6%), neoadjuvant chemotherapy yielded a pathologic complete response of 19.2% and a disease progression rate of 46.2%. Multivariate analysis showed that adjuvant radiation therapy significantly improved overall survival and disease-free survival, with hazard ratios of 0.29 (95% CI, 0.13-0.62; P < .005) and 0.23 (95% CI, 0.10-0.50; P < .005), respectively. Clinical T3 and T4 stages and nodal involvement were associated with poor outcomes. Stable disease after neoadjuvant chemotherapy was associated with poor overall survival and disease-free survival. Conclusions: This study sheds light on the complex landscape of MBC and emphasizes the pivotal role of adjuvant radiation therapy in enhancing patient outcomes. Despite advancements, challenges persist that warrant continued research to refine neoadjuvant chemotherapy strategies and delve into the nuanced factors that influence treatment responses.
Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis

Meghana Kesireddy,Lina Elsayed,Valerie K. Shostrom,Priyal Agarwal,Samia Asif,Amulya Yellala,Jairam Krishnamurthy

DOI: https://doi.org/10.3390/cancers16101791

2024-05-08

Cancers

Abstract:Background: Metastatic triple-negative breast cancer (TNBC) is aggressive with poor median overall survival (OS) ranging from 8 to 13 months. There exists considerable heterogeneity in survival at the individual patient level. To better understand the survival heterogeneity and improve risk stratification, our study aims to identify the factors influencing survival, utilizing a large patient sample from the National Cancer Database (NCDB). Methods: Women diagnosed with metastatic TNBC from 2010 to 2020 in the NCDB were included. Demographic, clinicopathological, and treatment data and overall survival (OS) outcomes were collected. Kaplan–Meier curves were used to estimate OS. The log-rank test was used to identify OS differences between groups for each variable in the univariate analysis. For the multivariate analysis, the Cox proportional hazard model with backward elimination was used to identify factors affecting OS. Adjusted hazard ratios and 95% confidence intervals are presented. Results: In this sample, 2273 women had a median overall survival of 13.6 months. Factors associated with statistically significantly worse OS included older age, higher comorbidity scores, specific histologies, higher number of metastatic sites, presence of liver or other site metastases in those with only one metastatic site (excluding brain metastases), presence of cranial and extra-cranial metastases, lack of chemotherapy, lack of immunotherapy, lack of surgery to distant sites, lack of radiation to distant sites, and receipt of palliative treatment to alleviate symptoms. In the multivariate analysis, comorbidity score, histology, number of metastatic sites, immunotherapy, and chemotherapy had a statistically significant effect on OS. Conclusions: Through NCDB analysis, we have identified prognostic factors for metastatic TNBC. These findings will help individualize prognostication at diagnosis, optimize treatment strategies, and facilitate patient stratification in future clinical trials.

oncology
Clinicopathological Characteristics and Prognostic Risk Factors of Breast Cancer Patients with Bone Metastasis

Yuanxing Pan,Yunfei Lin,Chuan Mi

DOI: https://doi.org/10.21037/atm-21-4052

IF: 3.616

2021-01-01

Annals of Translational Medicine

Abstract:Background: A retrospective study was performed to summarize the clinicopathological characteristics of breast cancer patients with bone metastasis, to clarify the metastasis sites, and to explore the risk factors affecting prognosis. Methods: Breast cancer patients with bone metastasis diagnosed in our hospital from January 2008 to January 2019 were included. Through follow-up by telephone call or return visit, the metastasis sites and clinicopathological characteristics were summarized. The risk factors influencing prognosis were analyzed by univariate and multivariate regression analyses. Results: Multifocal bone metastases were dominant in the 150 patients, and the metastatic rates in the spine, chest, pelvis, limbs, and skull were 75.3%, 74.0%, 56.0%, 46.7%, and 28.7%, respectively, with significant differences (P<0.01). Kaplan-Meier univariate analysis showed that age, menstrual status, number of metastatic lymph nodes, clinical stage, endocrine therapy, alkaline phosphatase level, visceral metastasis, and number of bone metastasis sites affected the overall survival. Cox multivariate regression analysis revealed that endocrine therapy, number of metastatic lymph nodes, visceral metastasis, number of bone metastasis sites, and c-erbB-2 expression were independent prognostic factors. Conclusions: Middle-aged and elderly patients with breast cancer, mainly aged 40-60 years old, are prone to bone metastasis. The incidence rate of bone metastasis is high within 3 years after surgery, involving the spine, chest, pelvis, limbs, and skull in descending order. The number of metastatic lymph nodes, endocrine therapy, visceral metastasis, number of bone metastasis lesions at the first onset, and c-erbB-2 expression are independent prognostic factors influencing the survival rate of breast cancer patients with bone metastasis.
Novel Nomograms to Predict of Overall Survival and Cancer-specific Survival of Patients of Metaplastic Breast Cancer

Yongfeng Li,Daobao Chen,Haojun Xuan,Mihnea P. Dragomir,George A. Calin,Hongjian Yang,Meng Chen,hongchuan Jin

DOI: https://doi.org/10.21203/rs.3.rs-96114/v1

2020-01-01

Abstract:Abstract Background Metaplastic breast cancer (MBC) is a rare type of breast cancer with an increasing incidence, we aim to develop clinical nomograms to predict the overall survival and cancer-specific survival for patients with MBC.MethodsPatients data were collected from the SEER database between 1973 and 2015. All included patients were randomly assigned into the training and validation sets. Univariate and multivariate Cox analysis were performed to identify independent prognostic factors of MBC. These essential prognostic variables were combined to construct nomogram models to predict overall survival (OS) and cancer-specific survival (CSS) in patients with MBC. Model performance was evaluated by concordance index (C-index) and calibration plots.ResultsA total of 1835 patients were collected and divided into the training (1223) and validation (612) groups. The multivariate Cox model identified age, TNM stage, T stage, and N stage, chemotherapy and radiotherapy as independent covariates associated with OS, while these variables except for age and chemotherapy were independent prognostic factors of CSS. The nomogram constructed based on these covariates demonstrated excellent accuracy in estimating 3-, and 5-year OS and CSS, with a C-index of 0.759 (95% CI, 0.746-0.772) for OS and 0.766 (95% CI, 0.751-0.781) for CSS in the training cohort. In the validation cohort, the nomogram-predicted C-index was 0.754 for OS (95%CI, 0.734-0.774) and 0.752 (95%CI, 0.728-0.776) for CSS. All calibration curves exhibited good consistency between predicted and actual survival.ConclusionsThese nomogram models established in this study can help to enhance the accuracy of prognostic prediction, which may thereby improve individualized assessment of survival risks and facilitate to provide constructive therapeutic suggestions.
Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‐centre experience

Mirosława Püsküllüoğlu,Katarzyna Swiderska,Aleksandra Konieczna,Joanna Streb,Aleksandra Grela‑Wojewoda,Agnieszka Rudzinska,Jolanta Dobrzańska,Renata Pacholczak‑Madej,Anna Mucha‑Malecka,Michał Kunkiel,Jerzy Mitus,Michał Jarząb,Marek Ziobro

DOI: https://doi.org/10.3892/ol.2024.14331

2024-03-09

Oncology Letters

Abstract:Metaplastic breast cancer (BC‐Mp), which includes a range of epithelial and mixed epithelial‐mesenchymal tumours, are rare malignancies with an unfavourable prognosis. The limited literature on BC‐Mp focuses mainly on retrospective data for radically treated patients. Notably absent are studies dedicated to the palliative treatment of BC‐Mp with distant metastases. The present retrospective study investigated treatment modalities and prognosis in a multi‐centre cohort of 31 female participants diagnosed with distant metastatic BC‐Mp, including 7 patients with de novo metastatic disease. The median age of the patients was 61 years (range, 33‐87 years), with 38.7% presenting local lymph node involvement. Lungs were the most common site for the metastatic disease (61.3%). Median Ki‐67 index was 50% (range, 35‐70%), and 80.7% of cases were classified as grade 3. Human epidermal growth factor receptor 2 (HER2)+ and estrogen receptor+ were detected in 12.9 and 6.5% of cases, respectively. A total of 62.4% of patients received first‐line palliative systemic treatment. The 1‐ and 2‐year overall survival (OS) were 38.5 and 19.2%, respectively. Receiving ≥1 line of palliative treatment was significantly associated with improved OS (P<0.001). Factors such as age, Ki‐67 index, HER2 or hormonal status, presence of specific epithelial or mesenchymal components, location of metastases or chemotherapy regimen type did not influence OS. The present study provided insights into the clinicopathological profile, systemic treatment experience, prognostic factors and OS data of BC‐Mp with distant metastases, emphasizing the imperative for clinical trials in this population.

oncology
Clinical characteristics and prognostic analysis of metachronous bilateral breast carcinoma: a retrospective study based on propensity score matching

Xinle Wang,Xinrui Wang,Lijing Cai,Cong Zhang,Yuntao Li

DOI: https://doi.org/10.1007/s12094-024-03528-y

Abstract:Background: To investigate clinical characteristics, treatment, outcomes, and prognostic risk factors of metachronous bilateral breast carcinoma (MBBC) and provide a theoretical basis for clinical management of MBBC. Methods: This was a retrospective study. From January 1, 2010 to March 31, 2022, a total of 23,010 patients with breast cancer underwent surgical treatment at the Breast Center of the Fourth Hospital of Hebei Medical University, including 386 patients with MBBC. Propensity score matching (PSM) was performed on MBBC patients and unilateral breast cancer (UBC) patients in a 1:1 ratio, and 210 UBC patients and 210 MBBC patients were finally matched. Clinical medical records of all patients were collected, including age of onset, family history of breast cancer, tumor size, lymph node status, TNM stage, mode of surgery, menstruation, pathological type, immunohistochemical (IHC) typing, treatment, disease-free survival (DFS), and overall survival (OS). Results: The result showed that age of onset of the second primary cancer (SPC) was significantly older than that of the first primary cancer (FPC) (P = 0.024). Baseline data from MPPC patients showed that the tumor size of FPC was significantly larger than that of SPC (P = 0.043), and the proportion of PR ( +) in FPC is significantly higher than that in SPC (P = 0.045). Among MBBC patients with FPC for estrogen receptor (ER) or progesterone receptor (PR) ( +) and Her-2 (-), clinical characteristics and treatment results showed that the proportion of PR ( +) in the drug-resistant group was significantly lower than that in the non-drug-resistant group. The 2-year OS rate of SPC in the drug-resistant group was significantly shorter than those of the non-drug-resistant group (78.9% vs 100%, P < 0.05). The result of PSM-based comparison between MBBC patients and UBC patients showed significantly lower proportion of MBBC patients with SPC received chemotherapy compared to UBC patients (P = 0.026), and there was no significant difference in OS and DFS between SPC course of MBBC patients and UBC patients (P > 0.05). The univariate analysis showed that high TNM stage was a risk factor for death and disease progression in MBBC patients, with the risk of death in stage III MBBC patients being about 5 times higher than that in stage I MBBC patients (HR = 4.97, 95%CI = 1.42-17.31, P = 0.012), and the risk of disease recurrence being about 3.5 times higher than that in stage I MBBC patients (HR = 3.55, 95%CI = 1.07-11.81, P = 0.039). Conclusion: In summary, this study presented clinical characteristics, treatment options, and outcomes of MBBC patients and patients with MBBC who were resistant to endocrine therapy have a worse SPC survival prognosis. The course of SPC in MBBC patients was similar to that of UBC in terms of prognosis and survival, which suggested that SPC can be treated according to UBC treatment regimen. High TNM stage was a prognostic risk factor for SPC patients.
Metastatic Trends in Breast Cancer According to Molecular Subtypes, Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2neu Status

Garima Uikey,Hemant Ahirwar,Rajesh Kori,Suresh Yadav,Om Prakash Singh,Rishika Saxena,Sachet Saxena,,Veenita YogI

DOI: https://doi.org/10.46347/jmsh.v8i2.21.173

2022-09-15

Journal of Medical Sciences and Health

Abstract:Background : Breast cancer molecular subtypes have been established a close relationship with site specific metastasis, disease prognosis, selection of therapy and response to therapy. This study is the evaluation of primary tumor molecular determinants and its clinical outcome in association with metastatic behavior of breast cancer. Material and Methods: This prospective study was included 221 patients of breast cancer registered in the department between January 2016 to December 2018. Based upon hormonal status, patients with breast cancer were categorized into four groups i.e. luminal (ER+, PR+, HER 2neu-), HER 2neu enriched (ER-, PR-, HER 2neu+), triple positive (ER+, PR+, HER 2neu+) and triple negative (ER-, PR-, HER 2neu-). Metastatic sites were divided into skeleton and visceral (lung, liver, and brain). The study data was compiled using Microsoft Excel sheet and Chi-Square test was used to assess the association between categorical variables. P value less than 0.05 was considered as statistically significant. Results : The mean age of the patients was 48.21±11.4 years (ranging from 22 to 80 years). About 36.7% and 24.9% patients were diagnosed as stage III A and stage II B respectively. Majority of patients were categorized as luminal (43%), followed by 24%, 17.2% and 15.8% as triple negative, triple positive and HER 2neu enriched respectively. Metastasis to bone following breast cancer was observed in majority i.e. 11.8% cases. Lung and liver metastasis observed in 6.3% cases each whereas brain metastasis was observed in 0.9% cases only. The higher proportions of TNBC cases metastasized to bone (22.6%), liver (7.5%), lung (7.5%) and brain (1.9%). The association between metastasis and hormonal status was statistically highly significant for bone metastasis (p<0.05). Conclusion : Breast cancer molecular subtypes have been related to considerable distinction in pattern of distant spread. Bone is the most predominant site of metastases followed by liver lung and brain. Luminal and HER 2 neu enriched subtypes having greater propensity for visceral metastasis where as TNBC predominantly show bone metastasis in this study. Keywords: Breast cancer, molecular subtypes, site-specific metastasis
Metaplastic Breast Carcinoma in U.S. Population: Racial Disparities, Survival Benefit of Adjuvant Chemoradiation and Future Personalized Treatment with Genomic Landscape

Asad Ullah,Jaffar Khan,Abdul Qahar Khan Yasinzai,Katharine Tracy,Tena Nguyen,Bisma Tareen,Andrea Agualimpia Garcia,Saleh Heneidi,Sheila E Segura

DOI: https://doi.org/10.3390/cancers15112954

2023-05-28

Abstract:Purpose: In this population-based study, we aim to identify factors that are influential on the survival outcome in MBC and investigate novel molecular approaches in personalized disease management. Methods: The data of this study were collected from the SEER database from 2000-2018. A total of 5315 cases were extracted from the database. The data were evaluated for demographics, tumor characteristics, metastasis, and treatment. Survival analysis was completed by using SAS software for multivariate analysis, univariate analysis, and non-parametric survival analysis. The molecular data with the most common mutations in MBC were extracted from the Catalogue of Somatic Mutations in Cancer (COSMIC) database. Results: The mean age at the time of presentation was 63.1 with a standard deviation (SD) of 14.2 years. Most patients were White (77.3%) with 15.7% Black patients, 6.1% Asian or Pacific Islander, and 0.5% American Indian. Histologically, most of the reported tumors were grade III (74.4%); 37% of the cases were triple negative (ER-, PR- and HER2-), whereas the hormone status was unknown in 46% of the cases. Spread was localized in 67.3% of patients while 26.3% had regional spread and 6.3% had distant metastases. Most tumors were unilateral (99.9%) and between 20-50 mm in size (50.6%). The lungs were the most common site for distant metastasis at diagnosis (3.42%) followed by bone (1.94%), liver (0.98%), and brain (0.56%). A combination of surgery, chemotherapy, and radiation therapy was the most common treatment with a cause-specific survival rate of 78.1% (95% CI = 75.4-80.4). The overall survival rate at 5 years was 63.6% (95% confidence interval (CI) = 62.0-65.1) with a cause-specific survival of 71.1% (95% CI = 69.5-72.6). Cause-specific survival was found to be 63.2% (95% CI = 58.9-67.1) in Black patients as compared to 72.4% (95% CI = 70.1-74.1) in White patients. Black patients also presented with higher rates of grade III disease, distant metastasis, and larger tumor size. On multivariate analysis, age > 60, grade III+, metastasis, and tumor size > 50 mm were associated with worse survival. The most common mutations in MBC identified in COSMIC data were TP53, PIK3CA, LRP1B, PTEN, and KMT2C. Conclusion: Though rare, MBC is aggressive, with poor prognosis associated with high-grade tumors, metastasis, tumor size over 50 mm, and advanced age at the time of presentation. Overall, Black women had worse clinical outcomes. MBC is difficult to treat and carries a poor prognosis that affects various races disproportionately. Continued enhancement of treatment strategies to foster more individualized care as well as continued enrollment in clinical trials are needed to improve outcomes among patients with MBC.
A bibliometric analysis of metastatic breast cancer: two-decade report (2002-2022)

Siyuan Jiang,Qingjie Meng,Fuqing Ji,Yulong Yin,Xianghua Liu,Wenzhen Shi,Yonggang Lyu

DOI: https://doi.org/10.3389/fonc.2023.1229222

2023-08-24

Abstract:Background: MBC is a lethal form of breast cancer that arises when cancer cells invade other organs or tissues. The treatment of MBC needs personalized approaches based on the tumor and patient characteristics. The purpose of this paper is to analyze MBC studies from 2002 to 2022 using bibliometrics and to investigate its current situation, main contributors, core journals, highly cited papers, and topic evolution. Materials and methods: We retrieved data from Web of Science Core Collection (WOSCC). Bibliometric analysis of the included literatures mainly used the following tools: the function of "analyze results" and "citation report" in WoS, Microsoft excel 2021, CiteSpace v.6.1. R6, VOSviewer v.1.6.18, BICOMB v.2.04 and gCLUTO v.1.0. Results: We found 12,653 articles on MBC research published in 1, 802 journals by 69, 753 authors from 118 countries. The annual output and citation of MBC articles showed a rising trend over time. The United States was the most influential country in MBC research. The most cited journal in this field was The Journal of Clinical Oncology. And the most cited article was by Slamon DJ. The co-word analysis of keywords divides MBC into six research clusters. The hormone receptor-positive MBC and liquid biopsy of MBC are the frontiers research trends. "CDK4/6 inhibitor" had the highest burst strength. Conclusion: Our bibliometric analysis offers a comprehensive overview of MBC research in the past two decades. It shows the current situation, main contributors, core journals, highly cited papers, and topic evolution of this field. Our study can assist researchers and practitioners to comprehend the development and trends of MBC research and to discover potential directions for future research.
Current Management of Brain Metastases in Breast Cancer

Erkan Güler,Bilal Arslan,Ahmet Dağ

DOI: https://doi.org/10.1007/s12262-024-04030-z

2024-01-18

Indian Journal of Surgery

Abstract:This study aims to evaluate the clinical features, prognostic factors, and survival of patients treated in our clinic for brain metastases of brain cancer. A total of 840 patients who were followed up with a diagnosis of breast cancer between 2012 and 2022 were included in the study. Brain metastasis was detected in 38 (4.5%) patients, and we excluded two of these patients whose data were not fully available. Thirty-six patients with brain metastases were evaluated. The demographic and clinical characteristics of the patients, stage of breast cancer (according to TNM classification), histopathology of the tumor, chemotherapy-hormonal therapy history, brain metastasis and detection time, disease-free, and mean survival time were examined. Brain metastasis was detected in 38 (4.5%) patients, and we excluded two of these patients whose data were not fully available. The remaining 36 patients were women. Brain metastases were detected in 20 patients during breast cancer diagnosis and 16 patients during follow-up.In primary tumor evaluation, 30% of the patients were triple negative, and %33% Her2( +). Surgery was performed in 14 patients (39%) with brain metastasis. Radiotherapy was applied to 28 (77%) patients, and stereotactic radiosurgery/gamma knife was applied to 4 (11%) patients. The risk factors in managing brain metastases in breast cancer are crucial in evaluating patients' symptoms and using early diagnosis and treatment options. Suitable patients may benefit from surgery. New chemotherapy agents, such as third-generation taxanes, are in development for the specific indication of brain metastases. Targeted medical and multimodal minimally invasive interventions are potential future treatment procedures for brain metastasis.

surgery
Genomic characterization of metastatic breast cancers

François Bertucci,Charlotte K. Y. Ng,Anne Patsouris,Nathalie Droin,Salvatore Piscuoglio,Nadine Carbuccia,Jean Charles Soria,Alicia Tran Dien,Yahia Adnani,Maud Kamal,Séverine Garnier,Guillaume Meurice,Marta Jimenez,Semih Dogan,Benjamin Verret,Max Chaffanet,Thomas Bachelot,Mario Campone,Claudia Lefeuvre,Herve Bonnefoi,Florence Dalenc,Alexandra Jacquet,Maria R. De Filippo,Naveen Babbar,Daniel Birnbaum,Thomas Filleron,Christophe Le Tourneau,Fabrice André

DOI: https://doi.org/10.1038/s41586-019-1056-z

IF: 64.8

2019-05-01

Nature

Abstract:Metastasis is the main cause of death for patients with breast cancer. Many studies have characterized the genomic landscape of breast cancer during its early stages. However, there is evidence that genomic alterations are acquired during the evolution of cancers from their early to late stages, and that the genomic landscape of early cancers is not representative of that of lethal cancers<a href="#ref-CR1">1</a>,<a href="#ref-CR2">2</a>,<a href="#ref-CR3">3</a>,<a href="#ref-CR4">4</a>,<a href="#ref-CR5">5</a>,<a href="#ref-CR6">6</a>,<a href="/articles/s41586-019-1056-z#ref-CR7">7</a>. Here we investigated the landscape of somatic alterations in 617 metastatic breast cancers. Nine driver genes (TP53, ESR1, GATA3, KMT2C, NCOR1, AKT1, NF1, RIC8A and RB1) were more frequently mutated in metastatic breast cancers that expressed hormone receptors (oestrogen and/or progesterone receptors; HR+) but did not have high levels of HER2 (HER2−; n = 381), when compared to early breast cancers from The Cancer Genome Atlas. In addition, 18 amplicons were more frequently observed in HR+/HER2− metastatic breast cancers. These cancers showed an increase in mutational signatures S2, S3, S10, S13 and S17. Among the gene alterations that were enriched in HR+/HER2− metastatic breast cancers, mutations in TP53, RB1 and NF1, together with S10, S13 and S17, were associated with poor outcome. Metastatic triple-negative breast cancers showed an increase in the frequency of somatic biallelic loss-of-function mutations in genes related to homologous recombination DNA repair, compared to early triple-negative breast cancers (7% versus 2%). Finally, metastatic breast cancers showed an increase in mutational burden and clonal diversity compared to early breast cancers. Thus, the genomic landscape of metastatic breast cancer is enriched in clinically relevant genomic alterations and is more complex than that of early breast cancer. The identification of genomic alterations associated with poor outcome will allow earlier and better selection of patients who require the use of treatments that are still in clinical trials. The genetic complexity observed in advanced breast cancer suggests that such treatments should be introduced as early as possible in the disease course.

multidisciplinary sciences
Abstract P1-05-31: A Single Center Retrospective Analysis of 259 Cases of Metaplastic Breast Cancer

Douwaner Liu,Jiajian Chen,Shuang Hao,Bingqiu Xiu,Qi Zhang,Liyi Zhang,Guangyu Liu,Zhimin Shao,Jiong Wu

DOI: https://doi.org/10.1158/1538-7445.sabcs22-p1-05-31

IF: 11.2

2023-01-01

Cancer Research

Abstract:Abstract Introduction: Metaplastic breast cancer (MBC) is a rare breast tumor.WHO histological classification of breast tumors in 2019 divided MBC into the following seven types: low-grade adenosquamous carcinoma, fibromatoid metaplastic carcinoma, squamous cell carcinoma, spindle cell carcinoma, metaplastic carcinoma with mesenchymal differentiation, mixed metaplastic carcinoma and myoepithelial carcinoma. Based on single center data, this study intends to conduct a detailed analysis of the clinicopathological features, treatment and prognostic factors of MBC. Methods:We collected 259 MBCs treated in our center from 2006 to 2022. The patient’s age, histological type, image feature, tumor size, lymph node metastasis, tumor stage, immunohistochemical information, surgical plan and systemic adjuvant therapy were summarized and considered to explore the factors affecting the overall survival rate (OS) and disease-free survival rate (DFS). T-test and chi-square test were performed on the data. P< 0.05 showed that the difference was statistically significant. Kaplan-Meier survival was used to analyze the long-term efficacy. Results: The incidence rate of MBC in breast cancer patients in our center is about 0.5%. They included 105 cases of squamous cell carcinoma (40.5%), 49 cases of mixed metaplastic carcinoma (18.9%), 41 cases of spindle cell carcinoma (15.8%), 27 cases of metaplasia carcinoma secreting matrix (10.4%), 6 cases of metaplastic carcinoma with mesenchymal differentiation (2.3%), 6 cases of myoepithelial carcinoma (2.3%), 3 cases of low-grade adenosquamous carcinoma (1.2%), 1 case of fibromatoid metaplasia carcinoma (0.4%) and 21 cases of unknown (8.1%). MBC were mainly three negative subtypes, which were 204 cases (78.8%), 41 cases (15.8%) luminal subtypes and 14 cases (5.4%) HER2 positive subtypes. There was no significant difference in the distribution of breast cancer subtypes among different histological types of MBC. There were 63 cases (24.3%) in clinical stage I, 171 cases (66.0%) in stage II, 23 cases (8.9%) in stage III and 2 cases (0.8%) in stage IV. 58 patients underwent core needle biopsy, of which only 7 (12.1%) reported histological types consistent with MBC. Among 154 patients with molybdenum target reports, 59 of them (38.3%) had malignant calcifications. The diagnostic coincidence rates of MRI, ultrasound and molybdenum target were 90.0%, 85.1% and 74.7% respectively. 258 cases of MBC received surgical treatment, including 183 cases of total mastectomy (70.9%), 53 cases of breast conserving surgery (20.5%) and 22 cases of quadrant resection (8.5%); 132 patients (51.2%) underwent axillary lymph node dissection and 93 patients (36.0%) underwent sentinel lymph node biopsy. 24 patients (9.3%) received neoadjuvant chemotherapy, of which only 2 (8.3%) achieved pathological complete remission. 56 patients (21.6%) received adjuvant radiotherapy, with a median of 25 times. 167 patients (64.5%) received adjuvant chemotherapy, and anthracycline sequential paclitaxel was the most commonly used regimen. The median follow-up was 31 months. The five-year DFS was 82.0%, and the five-year OS was 89.4%. Through Cox regression analysis, it was found that patients’ N stage (P=0.036) and receiving anthracycline sequential paclitaxel adjuvant chemotherapy (P=0.004) were independent prognostic factors. Conclusion: The histological types of MBC are complex. MRI is of high value in diagnosis. Conventional CNB is difficult to meet the needs of pathological tissue classification. Patients without lymph node metastasis and receiving anthracycline sequential paclitaxel adjuvant chemotherapy are associated with better prognosis. Through multidisciplinary standardized diagnosis and treatment, there is no significant difference between the prognosis of MBC and the common types of breast cancer. Keyword: metaplastic breast cancer; pathological characteristics; imaging; treatment; prognosis. Citation Format: Douwaner Liu, Jiajian Chen, Shuang Hao, Bingqiu Xiu, Qi Zhang, Liyi Zhang, Guangyu Liu, Zhimin Shao, Jiong Wu. A single center retrospective analysis of 259 cases of metaplastic breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P1-05-31.
Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study

Mirosława Püsküllüoğlu,Aleksandra Konieczna,Katarzyna Świderska,Joanna Streb,Małgorzata Pieniążek,Aleksandra Grela-Wojewoda,Renata Pacholczak-Madej,Anna Mucha-Małecka,Jerzy W Mituś,Joanna Szpor,Michał Kunkiel,Agnieszka Rudzińska,Michał Jarząb,Marek Ziobro

DOI: https://doi.org/10.2340/1651-226X.2024.40413

2024-08-04

Abstract:Background and purpose: Metaplastic breast carcinoma (BC-Mp) is an uncommon subtype that poses unique challenges. The limited information on patient prognosis and therapeutic strategies motivated our research initiative. We aimed to assess disease-free survival (DFS), overall survival (OS), and influential factors in patients with nonmetastatic BC-Mp. Materials and methods: In this multicenter retrospective cohort study, clinicopathological data for nonmetastatic BC-Mp patients treated at four oncology units in Poland (2012-2022) were gathered. Results: Among 115 women (median age 61, range: 28-91), the median tumor size was 40 mm (range 20-130); 30% of patients exhibited positive local lymph nodes. The majority of patients presented with stage II (46%) and triple-negative breast cancer (TNBC) (84%). Radiotherapy was administered to 61% of patients. Surgical procedures included breast-conserving surgery in 31% of patients and mastectomy in 68%. Eighty-three per cent of patients received chemotherapy. The median estimated DFS and OS were 59 and 68 months, respectively. Multivariable analysis revealed that tumor size influenced DFS and OS (Hazard ratios [HR] = 1.02, 95%CI 0.01-0.03 for both endpoints) and taxanes application improved DFS (HR = 0.47, 95%CI 0.24-0.93), but other factors did not. For patients receiving neoadjuvant systemic therapy (N = 51), taxanes improved DFS and OS according to univariable analysis. Interpretation: Our findings highlight poor DFS and OS regardless of receiving optimal treatment, emphasizing the need for tailored therapeutic strategies for BC-Mp patients. Taxanes appear promising in a neoadjuvant setting, particularly within the current standard of care for the TNBC subtype.
The conundrum of metaplastic breast cancer: a single Egyptian institution retrospective 10-year experience (2011-2020)

Yahia Ismail,Amr Kamal,Rasha Allam,Al-Shimaa Zakaria

DOI: https://doi.org/10.1186/s43046-023-00178-z

2023-06-05

Abstract:Background: Metaplastic breast cancer (MetBC) still represents a conundrum owing to its peculiar histogenesis and molecular drivers that render it extremely resistant to standard chemotherapy with ultimate dismal survival. Aim: Describe the Egyptian National Cancer Institute's (NCI-E) experience with MetBC regarding its clinicopathologic features, treatment, and survival outcomes. Patients and methods: Between 2011 and 2020, all MetBC patients presented to NCI-E were retrospectively evaluated. Original clinicopathologic data, therapeutic modalities, pathologic response to neoadjuvant chemotherapy (NACT), recurrence, and date of last follow-up/death were obtained from archived charts. Results: A cohort of 135 females, the median age was 52 years, and median follow-up period was 40 months (range: 2.6-130.8). Two-thirds were triple negative (TN). Squamous carcinoma was prevalent in 74.8% followed by carcinoma with osseous/chondroid differentiation, spindle cell, and low-grade adenosquamous carcinoma encountered in 13.3, 7.4, and 4.5%, respectively. Modified radical mastectomy was done in 59.3%, and positive nodes (pN+) were depicted in 37.7%. Median Ki-67 was 45% (range: 10-88); grade III and lymphovascular invasion (LVI) were observed in 83.7 and 43.7%, respectively. Stage II was the most common (49%), whereas initial stage IV was encountered in 8.1%. Anthracyclines/taxane combinations were rampant in adjuvant/neoadjuvant settings. The latter was employed in 41 patients, with only 3 cases (7.3%) achieving pathologic complete response (pCR), while moderate/significant residual tumor burden was found in 83%. The 5-year DFS and OS were 56.4 and 57.6%, respectively. Spindle cell carcinoma showed the worst survival parameters in univariate analysis. On the multivariate level, higher tumor stage (pT3 & 4), Ki-67 ≥ 45%, and TN subtype were independent variables for worse DFS and OS; age ≥ 52 years and the presence of LVI were independent features for worse DFS, whereas pN+ was an independent parameter for worse OS. Conclusions: This study further solidifies the dreadful response of MetBC to conventional chemotherapy regimens employed in common non-metaplastic pathologies. A radical shift in treatment standards tailored to combat the molecular landscape of this distinctive tumor is urgently needed. Immunotherapy and molecularly targeted agents demonstrated promising results in phase I and II trials with hopeful sooner implementation in phase III studies.
A Retrospective Cohort Study Evaluating Treatment Outcomes, Prognostic Factors, and Overall Survival

Carly M. Cooke,M. Ege Babadagli,Hillary Wilson,Vimoj J. Nair,Krystine Lupe,Shawn Malone,Laura Burgess,Wylam Faught,Rajiv Samant,Tien Le

DOI: https://doi.org/10.3390/curroncol31120558

2024-11-30

Current Oncology

Abstract:(1) Background: The objectives of this study were to assess survival of patients with a diagnosis of brain metastases secondary to gynaecologic malignancy and the impact of clinicopathological factors on prognosis in this population. (2) Methods: A retrospective cohort of patients with gynaecologic cancers diagnosed with brain metastases treated with radiation at a tertiary care centre from 1 January 2004 until 30 September 2023 was studied. Kaplan–Meier method and log-rank test were used to evaluate survival, and cox regression was used to identify significant predictive factors of survival. (3) Results: In total, 103 patients were included in this study. Median age at diagnosis of brain metastases was 59 (range 30–94). Median survival time following diagnosis of brain metastases was 3.6 months (range 0.4–183.8). Survival was significantly longer for patients treated with surgery combined with radiation compared to radiation alone and with stereotactic radiosurgery (SRS) compared to whole brain radiation therapy (WBRT). Cox regression revealed that primary ovarian malignancy, extracranial disease at diagnosis, and ≥3 brain metastases were associated with poorer prognosis, and complete response to prior treatment was associated with more favourable prognosis. (4) Conclusions: Data from this study will assist in providing evidence-based prognostic information to patients with gynaecologic malignancy diagnosed with brain metastases.

oncology
Breast Cancer Survival Analysis Model

Rong-Ho Lin,Ching-Shun Lin,Chun-Ling Chuang,Benjamin Kofi Kujabi,Yen-Chen Chen

DOI: https://doi.org/10.3390/app12041971

2022-02-14

Applied Sciences

Abstract:(1) Background: Breast cancer (BC)—a leading cause of mortality in women globally—accounts for more than two million cases annually. BC was the most common cancer in Taiwan in 2015 and ranks among the top 10 malignancies in Taiwan. (2) Methods: We established a collection of BC survival and metastasis analyses using the Kaplan–Meier, logarithmic test, and Cox proportional hazard models to investigate the association among BC stages, different treatment modalities, and survival rate of patients with BC at various follow-up intervals. We also evaluated whether clinical prognostic factors had univariate and multivariate effects on the survival of patients with BC. Finally, we performed a metastasis analysis using the survival transition rate values of BC stages to develop a Markov chain and semi-Markov simulation model for BC and BC metastasis analysis, respectively. (3) Results: The Kaplan–Meier survival analysis revealed that the risk of BC treated with surgery was lower than that of those who did not receive surgery and the recommended treatment methods should be ranked by survival as follows: surgery, hormone therapy, chemotherapy, and radiation therapy (in descending order of risk). This is attributed to the predicted survival rate which ranges from 99.6% to 91.2%. Moreover, Cox’s treatment method considered the patient’s attributes and revealed a significant difference (p = 0.001). The Markov chain analyses determined the chance of metastasis at each stage, indicating that the lower the stage of BC, the greater the survival rate. (4) Conclusions: Patients’ treatment is influenced by different BC stages, and earlier detection presents better chances of survival and a greater probability of treatment success.

English Else
The crosstalk between metabolic reprogramming and epithelial-mesenchymal transition and their synergistic roles in distant metastasis in breast cancer

Liyan Yu,Yongni Chen,Yingyu Chen,Kangwei Luo

DOI: https://doi.org/10.1097/md.0000000000038462

IF: 1.6

2024-06-15

Medicine

Abstract:Breast cancer (BRCA), the most common malignant tumor in women worldwide, is the second leading cause of cancer-related deaths among women. Globally, an estimated 2.3 million new cases [ 1 ] and 685,000 deaths [ 2 ] occurred in 2020. In 2022, approximately 290,560 new cases and 43,780 deaths were reported in the United States alone. [ 3 ] It is now understood that breast cancer exhibits significant intra and inter-tumor heterogeneity. However, once distant metastasis occurs, the chances of long-term survival for patients decrease drastically. Metastatic breast cancer is rarely curable, and treatment generally focuses on palliative care. According to the American Cancer Society, stage IV patients have a 5-year relative survival rate of 26%, compared to nearly 100% for stage I patients. [ 2 ] Based on the presence or absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (ERBB2; formerly HER2) molecular markers, breast cancer can be classified into 3 main subtypes: hormone receptor-positive/ERBB2-negative (70% of patients), ERBB2-positive (15–20%), and triple-negative (lacking all 3 standard molecular markers; 15%). While early-stage breast cancer often has a favorable prognosis after comprehensive treatment (including surgery), the therapeutic outcomes for intermediate and late-stage breast cancer are limited. In this respect, triple-negative breast cancer has a median overall survival of about 1 year. [ 4 ] Therefore, assessing the risk of distant metastasis and recurrence of breast cancer is particularly important, which provide a basis for clinical decisions in treatments for breast cancer patients.

medicine, general & internal

Impotence following delayed repair of prostatomembranous urethral disruption.

Gastric Cancer with Breast Metastasis: Clinical Features and Prognostic Factors

Metastatic Breast Cancer: Prolonging Life in Routine Oncology Care

Curative Approaches for Metaplastic Breast Cancer: A Retrospective Cohort Outcome Review

Overall Survival and Prognostic Factors in Metastatic Triple-Negative Breast Cancer: A National Cancer Database Analysis

Clinicopathological Characteristics and Prognostic Risk Factors of Breast Cancer Patients with Bone Metastasis

Novel Nomograms to Predict of Overall Survival and Cancer-specific Survival of Patients of Metaplastic Breast Cancer

Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‐centre experience

Clinical characteristics and prognostic analysis of metachronous bilateral breast carcinoma: a retrospective study based on propensity score matching

Metastatic Trends in Breast Cancer According to Molecular Subtypes, Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2neu Status

Metaplastic Breast Carcinoma in U.S. Population: Racial Disparities, Survival Benefit of Adjuvant Chemoradiation and Future Personalized Treatment with Genomic Landscape

A bibliometric analysis of metastatic breast cancer: two-decade report (2002-2022)

Current Management of Brain Metastases in Breast Cancer

Genomic characterization of metastatic breast cancers

Abstract P1-05-31: A Single Center Retrospective Analysis of 259 Cases of Metaplastic Breast Cancer

Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study

The conundrum of metaplastic breast cancer: a single Egyptian institution retrospective 10-year experience (2011-2020)

A Retrospective Cohort Study Evaluating Treatment Outcomes, Prognostic Factors, and Overall Survival

Breast Cancer Survival Analysis Model

The crosstalk between metabolic reprogramming and epithelial-mesenchymal transition and their synergistic roles in distant metastasis in breast cancer